Welcome to our dedicated page for Pluri SEC filings (Ticker: PLUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pluri Inc. (PLUR) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. Pluri is a Nevada-incorporated biotechnology company that reports operating from Haifa, Israel and lists its common shares on Nasdaq and the Tel Aviv Stock Exchange. Through its filings, investors can review how Pluri describes its business, governance, capital structure and material events related to its cell-based platform and collaborative ventures.
Key documents for Pluri include current reports on Form 8-K, which the company uses to announce material agreements, board and leadership changes, equity awards and private placements. For example, recent 8-K filings describe a Securities Purchase Agreement with an entity beneficially owned by a director for a private placement of common shares and warrants, equity grants to executives and directors, and changes in board composition and committee membership following shareholder meetings. These filings also document matters such as Nasdaq listing rule compliance and shareholder voting results.
Investors analyzing PLUR can use annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) to understand the company’s description of its 3D cell expansion platform, its operations in regenerative medicine, foodtech, agtech, aesthetics and CDMO services, and its network of subsidiaries and collaborations. Proxy statements and related materials provide additional detail on board structure, compensation plans and shareholder proposals.
On Stock Titan, Pluri’s SEC filings are complemented by AI-powered summaries designed to highlight the main points of lengthy documents, such as complex agreements or governance disclosures. Users can quickly see what each filing covers, from private placement terms and warrant structures to board appointments and committee roles, and then drill down into the full text for deeper analysis. The filings page also helps track equity issuances, compensation-related grants and other regulatory information that may be relevant to understanding PLUR as a publicly traded biotechnology company.
Pluri Inc. (PLUR) CEO Yaky Yanay filed a Form 4 reporting equity awards on 10/15/2025. He acquired 39,050 restricted stock units at $0, which are fully vested, and 39,050 stock options with a $5 exercise price that are fully vested and expire on 10/15/2028.
Following these transactions, he beneficially owns 491,170 shares directly, plus 836 shares held indirectly through Yaacov Yanay Management Ltd. The filing lists his roles as Chief Executive Officer and Director and indicates it was filed by one reporting person.
Eitan Ajchenbaum, identified as a Director of Pluri Inc. (ticker PLUR), filed an initial Form 3 relating to an event on 09/10/2025. The filing states no securities are beneficially owned by the reporting person. The form was signed on 09/22/2025 and was filed by one reporting person.
Pluri Inc. filed a shelf registration/prospectus related to resale of 3,425,488 common shares by selling shareholders and discloses 8,155,948 shares outstanding as of September 16, 2025. The company will not receive proceeds from those resales, but could receive approximately $724,686 if outstanding warrants and pre-funded warrants are exercised for cash at exercise prices of $5.568 and $0.00001, respectively. The prospectus lists share-based instruments outstanding including stock options (weighted average exercise prices of $10.40 and $18.72 and others), 2,151,809 shares issuable upon exercise of warrants/pre-funded warrants at a weighted average exercise price of $4.27, and 564,564 shares issuable upon vesting of RS/RSUs. The Common Shares trade on Nasdaq under the symbol PLUR. The prospectus cautions that an investment is highly speculative and directs readers to the Risk Factors section.
Pluri Inc. is registering an additional 650,000 common shares that may be issued under its 2019 Equity Compensation Plan. These shares are intended to support future stock-based awards to employees, directors, and other service providers under the plan.
The company previously registered 584,375, 437,500, and 100,000 common shares for the same plan on earlier Form S-8 filings. The plan limits the total shares available to no more than 16% of Pluri’s common shares outstanding on a fully diluted basis before new awards are granted.
Pluri Inc. filed a Form S-8 to register an additional 80,000 common shares for issuance under its Amended 2016 Equity Compensation Plan. Shareholders approved this amended plan on June 30, 2025, extending the plan’s term and confirming that total awards granted in any year are capped at 2.75% of common shares outstanding on a fully diluted basis as of the prior December 31. The filing also updates legal and disclosure information by incorporating the latest annual report on Form 10-K for the year ended June 30, 2025, several recent Form 8-Ks, and key corporate governance documents by reference.
Pluri Inc. (PLUR) operates a 3D cell expansion platform applied across regenerative medicine, food-tech (Ever After Foods), AgTech and a CDMO business. The company reported continued operating losses (losses of $23,250 for year ended June 30, 2025) and negative operating cash flow of $18,211, and states it must secure additional liquidity to support commercialization and R&D. Pluri completed the Kokomodo acquisition (79% for 976,139 shares), recording $2,823 of identifiable intangible assets and $3,136 of goodwill. The company has an outstanding EIB loan (linked principal and accrued interest of $27,289 presented as short-term) and is in discussions to restructure its terms. Share financings and warrant/pre-funded-warrant issuances occurred in fiscal 2025, and shareholder approval was obtained for certain warrant classifications. The company regained compliance with Nasdaq listing standards.
Pluri Inc. reported that its board of directors elected Mr. Eitan Ajchenbaum to serve as a director, effective September 10, 2025, filling a vacancy created after Doron Birger’s service ended following the June 30, 2025 annual meeting. He will serve until the next general meeting at which directors are elected or as provided in the company’s bylaws.
Mr. Ajchenbaum, age 63, is a Certified Public Accountant in Israel with more than 30 years of senior executive and board experience in public and private companies. He currently serves as Chief Financial Officer and Deputy Chief Executive Officer of WeSure Global Tech Ltd., and previously held long‑term senior roles at Berkshire Hathaway Guard and other Israeli public companies.
He will serve as a non‑executive director with the same rights and privileges as other non‑executive directors, including information access, expense reimbursement, and D&O insurance coverage. He has been appointed Chairman of the Audit Committee, designated as an audit committee financial expert, and named sole member of the Board’s Investment Committee. The company states there are no special arrangements, family relationships, or related‑party transactions connected to his appointment.